JB Chemicals & Pharmaceuticals Ltd acquires Azmarda brand indicated for heart failure patients from Novartis AG, Switzerland for India in Rs 246 cr

by IANS |

New Delhi, April 8 (IANS) Considering the dire need for cardiological drugs amidst the rising incidence of Heart Failure and Hypertension in India, and to taking its acquisition drive forward, J.B. Chemicals and Pharmaceuticals Ltd., has acquired Azmarda from Novartis AG, Switzerland for India in Rs 246 crore.

Azmarda is a brand indicated for heart failure patients with reduced ejection fraction (HFrEF). Azmarda is in the top 300 IPM brands, and it will be the 6th brand of JBCPL to be in the top 300.

Indeed, the acquisition of Azmarda by JBCPL is a strategic move to strengthen its equity in the segment of cardiology. After Cilacar and Nicardia, Azmarda will be the next big drug in JBCPL's cardiology portfolio.

Heart failure is a progressive chronic syndrome characterised by decrease in functional status and quality of life. The burden of heart failure has increased to an estimated 23 million people, worldwide. In India, the prevalence was estimated to be around 1.2/1000 people in the INDUS study.

The Azmarda brand, a patented product, shall be affixed on the proprietary Novartis AG product, which is a pharmaceutical composition comprising of Valsartan and Sacubitril. It has recorded sales of Rs 76.8 crore as per IQVIA MAT February, 2022. The patented product is growing at around 35 per cent CAGR and is one of the fastest-growing molecules in the cardiology segment. With only three players in the market, this molecule will make JBCPL in the cardio segment stand out amongst the competitors.

The brand 'Azmarda' fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India as Swiss giant Novartis entrusts JBCPL considering it as one of the best cardio-metabolic players.

Latest News
More 'surgical strikes' in offing in Kashmir University Mon, May 16, 2022, 04:47 PM
Post-mortem of Bengali TV actress Pallavi Dey hints at suicide Mon, May 16, 2022, 04:45 PM
Goons create ruckus at Dalit's marriage function in MP, pelt stones at police Mon, May 16, 2022, 04:41 PM
RSS founder Hedgewar's speech in Karnataka board textbook likely to stir controversy Mon, May 16, 2022, 04:39 PM
80-hour regime: Ajit Pawar, Fadnavis 'ko gussa kyun aata hai' Mon, May 16, 2022, 04:37 PM
Facing stiff oppn, Kerala govt's K-Rail survey to go hi-tech Mon, May 16, 2022, 04:25 PM
UP govt to roll out road safety campaign Mon, May 16, 2022, 04:20 PM
Palestinian dies of wounds after being shot in West Bank Mon, May 16, 2022, 04:15 PM
Rahul visits Rajasthan's Beneshwar Dham after 3-day Chintan Shivir Mon, May 16, 2022, 04:15 PM
Lingayat community seeks OBC status, BJP in a fix Mon, May 16, 2022, 04:09 PM
MP police directed to monitor missionary schools over alleged conversions Mon, May 16, 2022, 04:03 PM
Kim issues special order on medicine supply against Covid outbreak Mon, May 16, 2022, 04:02 PM
Amid resentment, 11 Tripura ministers take oath Mon, May 16, 2022, 04:00 PM
Afghan journos restricted from covering security incidents Mon, May 16, 2022, 03:55 PM
CBI summons Trinamool MLA in connection with BJP worker's murder Mon, May 16, 2022, 03:42 PM